Page 162 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 6b
Table 1. Baseline patient demographic and clinical characteristics.
Characteristic
Sex Male Female
Age, years Median Range
≤ 65
> 65
WHO performance status 0-1
2
Unknown
Ann Arbor stage II
III
IV
B symptoms
LDH > ULN
Bulky disease (> 10 cm) BM involvement
Age-adjusted IPI risk group Low
Low-intermediate High-intermediate
High
Histology (central review) DLBCL
Other diagnosis or unclassifieda Not reviewed
Phenotypeb Germinal center Nongerminal center
MYC rearrangement
MYC SH
MYC plus BCL2 and/or BCL6c
No. (%)
R-CHOP-14 (n = 286)
145 (51) 141 (49)
66 18-80 140 (49) 146 (51)
254 (89) 30 (10) 2 (1)
53 (18) 88 (31) 145 (51)
112 (39) 183 (64) 83 (29) 30 (10)
22 (8) 107 (37) 132 (46) 25 (9)
251 (88) 11 (4) 25 (8)
124 of 200 (62) 76 of 200 (38)
14 of 104 (13)
4 of 14 10 of 14
RR-CHOP-14 (n = 288) 154 (53)
134 (47)
65 31-80 149 (52) 139 (48)
251 (87) 36 (13) 1 (0)
61 (21) 89 (31) 138 (48)
120 (42) 196 (68) 85 (30) 36 (13)
24 (8) 93 (33) 147 (51) 24 (8)
244 (85) 16 (6) 28 (10)
107 of 177 (60) 70 of 177 (40)
5 of 73 (7)
1 of 5 4 of 5
Abbreviations: BM, bone marrow; DLBCL, diffuse large B-cell lymphoma; IPI, International Prognostic Index; LDH, lactate dehydrogenase; R-CHOP, rituximab on day 1 of each cycle plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm A); RR-CHOP, rituximab on days 1 and 8 of first 4 cycles and day 1 of remaining cycles plus cyclophosphamide, doxorubicin, vincristine, and prednisone (arm B); SH, single hit; ULN, upper limit of normal.
aAppendix Table A1. bBased on standard Hans criteria. cAccording to WHO classification 2016; now classified as high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
After a median follow-up of 92 months (range, 1-131 months) in the 364 patients still alive, the median FFS and median PFS were not reached in the R-CHOP-14 arm and were both 101 months in the RR-CHOP-14 arm, and the median DFS
160